Mazloom E, Daneshpazhooh M, Shoormasti RS, et al. - Researchers conducted this pilot study to examine the efficacy of intralesional injection of rituximab (RTX) in the healing of pemphigus lesions, with lower doses and probable better safety profile than intravenous RTX. Two intralesional injections of biosimilar RTX, 5 mg/cm², were given to 11 Pemphigus patients with recalcitrant lesions. Pemphigus Disease Area Index, the patients’ satisfaction, quality of life, the disease activity, the number and size of lesions, the anti‐desmoglein (Dsg) 1 and 3 antibodies and the count of CD4 and CD19 cells have been evaluated during six months follow‐up. A statistically significant decrease was seen in the absolute count of CD19 + B cells. During the study, the concentration of anti‐desmoglein 3 antibody insignificantly decreased. Severe pain during injection was found to be the biggest complication. The findings showed that while the low dose of RTX contributes to a substantial decrease in CD19+ B lymphocytes, there was no parallel clinical efficacy.